Table 4.
The major COVID-19 vaccines entering clinical trials worldwide.
| Sponsor | Candidate vaccine | Registration ID | ETC |
|---|---|---|---|
| Henan Provincial Center for Disease Control and Prevention | Inactivated vaccine | ChiCTR2000031809 | 10 November 2021 |
| Henan Provincial Center for Disease Control and Prevention | Inactivated vaccine | ChiCTR2000032459 | 28 November 2021 |
| Sinovac Biotech Co., Ltd | Inactivated vaccine | NCT04352608 | 13 December 2020 |
| Shenzhen Geno-Immune Medical Institute | Lentiviral vector vaccine | NCT04299724, NCT04276896 | 31 July 2023 |
| Insitute of Biotechnology, Academy of Military Medical Sciences, PLA of China | Adenovirus vector vaccine | NCT04341389 | 31 January 2021 |
| CanSino Biologics Inc. | Adenovirus vector vaccine (Adenovirus Type 5 Vector) | NCT04313127 | 30 December 2020 |
| Inovio Pharmaceuticals | DNA vaccine (INO-4800) | NCT04336410 | November 2020 |
| Symvivo Corporation | DNA vaccine | NCT04334980 | 31 August 2021 |
| National Institute of Allergy and Infectious Diseases (NIAID) | mRNA vaccine (mRNA-1273) | NCT04283461 | 1 June 2021 |
| Biontech SE | 4 RNA vaccines | NCT04368728 | 27 January 2023 |
| Novavax | Recombinant Spike Protein Nanoparticle Vaccine | NCT04368988 | 31 July 2021 |
ECT: Estimated time of completion.